Johnnie B. Byrd, Sr. Alzheimer's Center& Research Institute - November is Alzheimer's Awareness Month - Click here for more deatails.

Newsletter

Kids' Corner

Kids' Corner
Contact Us for more information
Byrd Institute Research

Full List of Papers and Articles Submitted by Subawardees
or Byrd Researchers and ADRC Researchers

for the Period July 1, 2004 through September 5, 2007

  1. Abdullah L, Ait-Ghezala G, Crawford F, Crowell TA, Barker WW, Duara R, Mullan “The cyclooxygenase 2 -765 C promoter allele is a protective factor for Alzheimer's disease.”  Neurosci Lett. 2005 Nov 21; [Epub ahead of print].
  2. Acevedo A, Loewenstein DA, Agron J, Duara R., “Influence of sociodemographic variables on neuropsychological test performance in Spanish-speaking older adults,” J Clin Exp Neuropsychol. 2007 Jul;29(5):530-44.
  3. Ahmed Z, Shaw G, Sharma VP, Yang C, McGowan E, Dickson DW. The actin binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J Histochem Cytochem 2007;55:687-700.
  4. Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW. Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 4:1, 2007
  5. Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc. 2006;1:1671-9.
  6. Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, Dickson DW. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 2007;61:435-45.
  7. Amador-Ortiz C, Ahmed Z, Zehr C, Dickson DW. Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. Acta Neuropathol (Berl) 2006;113:245-52.
  8. Andel R, Crow M, Pedersen NL, Mortimer J, Crimmins E, Johansson B and Gatz M.  “Complexity of work and risk of Alzheimer’s disease: A population-based study of Swedish twins.”  J. Gerontol. B; Psychol. Sci. Soc. Sci. 2005;60:P251-258.
  9. Arendash, G.W., et al., “Caffeine Protects Alzheimer’s Mice Against Cognitive Impairment and Reduces Brain ß-Amyloid Production,” Neuroscience; 142:941-952, (2006).
  10. Arendash, G.W., et al., “Environmental Enrichment Improves Cognition in Aged Alzheimer’s Transgenic Mice Despite Stable ß-Amyloid Deposition,” NeuroReport, 15(2):1751-54 (2004).
  11. Arendash, G.W., et al., “Multi-Metric Behavioral Comparison of APPsw and P301L Models for Alzheimer’s Disease: Linkage of Poorer Cognitive Performance to TAU Pathology in Forebrain,” Brain Research, 1012:29-41 (2004).
  12. Bain, Lisa J., “A review of the “State of the Art” on Mild Cognitive Impairment: The Fourth Annual Symposium,” Alz & Dementia; 2:246-256 (2006).
  13. Barker WW, Luis C, Harwood D, Loewenstein D, Bravo M, Ownby R, Duara R. “The effect of a memory screening program on the early diagnosis of Alzheimer disease.”  Alzheimer Dis Assoc Disord. 2005 Jan-Mar; 19(1):1-7. 
  14. Bjugstad KB and Arendash, GW.  “Intracerebroventricular infusions of Gp120 inhibit weight gain and induce atrophy in the hippocampus and neostriatum without affecting cognition.”  J. NeuroAIDS 2005; 2:15-32.
  15. Boeras, DI, et al., “Alzheimer’s presenilin 1 causes chromosome missegregation and aneuploidy.” Neurobiology of Aging (2006) [Article in Press]
  16. Costa et al., “Apolipoprotein is required for the formation of filamentous amyloid, but not for amorphous Aβ deposition, in an AβPP/PS double transgenic mouse model of Alzheimer’s disease.” Jrnl. Of Alzheimer’s Disease 6 509-514 (2004)
  17. Costa, David A., et al., ”Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanism,” Neurobiol of Aging 2007 June;28(6): 831-844 (2007)
  18. Cracchiolo, J.R.; et al., “Enhanced cognitive activity – over and above social or physical activity – is required to protect Alzheimer’s mice against cognitive impairment, reduce Aβ deposition and increase synaptic area.” Neurobiology of Learning and Memory (2007) [Article in Press]
  19. Crocco, E.A. & Loewenstein, D.A.  “Psychiatric aspects of mild cognitive impairment.”  Current Psychiatry Reports, 2005; 7(1):32-36.
  20. Dickey et al., “Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels – Proof of Concept with HSP90 Inhibitors,” Current Alzheimer’s Research, 2(2):231-8 (2005).
  21. Dickson DW, Rademakers R, Hutton ML. Progressive supranuclear palsy: pathology and genetics. Brain Pathol. 2007;17:74-82.
  22. Ethell, Douglas W., et al., “Aβ-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer’s mice,” J.NNBD.23:351-361, (2006).
  23. Gitlin, L.N., Roth, D.L., Burgio, L.D., Loewenstein, D.A., Winter, L., Nichols, L., Arguelles, S., Corcoran, M., Burns & Martindale.  “Caregiver appraisals of functional dependence in individuals with dementia and associated caregiver upset: psychometric properties of a new scale and response patterns by caregivers and care recipient characteristics.” J. Aging and Health, 2005, 17(2):148-171.
  24. Giunta et al., “Galantamine and Nicotine Have a Synergistic Effect on Inhibition of Microglial Activation Induced by HIV-1 gp120,” Brain Research, 165-70 (2004).
  25. Glueckauf, R. L. & Ketterson, T. U., “Telehealth interventions for individuals with chronic illness: Research review and implications for practice.”  Professional Psychology: Research and Practice, 35:615-27 (2005).
  26. Glueckauf, R. L., “Caring for Older Adults with Alzheimer's Disease in a Small Rural Town: Can Telehealth Help?”  Register Report, 30:23-32 (2004).
  27. Glueckauf, R. L., Ketterson, T. U., Loomis, J. S., & Dages, P., “Alzheimer’s Caregiver Support Online: Findings of Strategic Marketing Initiative and Initial Program Evaluation.” Telemedicine Journal and e-Health 10: 223-232 (2004).
  28. Glueckauf, R. L., Young, M. E., Stine, C., Bourgeois, M., Pomidor, A., & Rom, P. (in press). “Alzheimer’s Rural Care Healthline: Linking Rural Dementia Caregivers to Cognitive-Behavioral Intervention for Depression.”  Rehabilitation Psychology, 50(4) (2004).
  29. Glueckauf, R., et al., “Alzheimer’s Rural Care Healthline: Linking Rural Caregivers to Cognitive-Behavioral Intervention for Depression,” Rehab. Psy., 50(4):346-354 (2005).
  30. Haley WE.  “Clinical geropsychology in primary care: Progress and Prospects.”  Clinical Psychology: Science and Practice, 2005; 12:336-338.
  31. Harwood DG, Barker WW, Ownby RL, Mullan M, Duara R.  “No association between subjective memory complaints and apolipoprotein E genotype in cognitively intact elderly.”  Int J Geriatr Pscyhiatry. 2004 Dec; 19(12):1131-9.
  32. Harwood DG, Barker WW, Ownby RL, St George-Hyslop P, Mullan M, Duara R.  “Apolipoprotein E polymorphism and age of onset for Alzheimer’s disease in a bi-ethnic sample.” Int Psychogeriatr. 2004 Sept; 16(3):317-26.
  33. Jang Y, Borenstein AR, Chiriboga DA and Mortimer JA.  “Depressive symptoms among African American and white older adults.”  J. Gerontol. B: Psychol. Sci. Soc. Sci. 2005; 60:P313-P319.
  34. Jensen M, Mottin, MD, Cracchiolo, JR, Leighty, RE, and Arendash, GW.  “Life-long immunization with human -amyloid (1-42) protects AD transgenic mice against cognitive impairment throughout aging.” Neuroscience 2005;130:667-684.
  35. Josephs KA, Ahmed Z, Katsuse O, Parisi JF, Boeve BF, Knopman DS, Petersen RC, Davies P, Duara R, Graff-Radford NR, Uitti RJ, Rademakers R, Adamson J, Baker M, Hutton ML, Dickson DW. Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol. 2007;66:142-51
  36. Karlnoski R, Wilcock D, Dickey C, Ronan V, Gordon MN, Zhang W, Morgan D, Taglialatela G. Up-regulation of Bcl-2 in APP transgenic mice is associated with neuroprotection. Neurobiol Dis. 2007;25:179-88.
  37. Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, Golde TE, Nicolle MM. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor  rotein mice. BMC Neurosci. 2007 Jul 24;8:54.
  38. Kutzler MA, Cao C., Bai Y, Dong H, Choe PY, Saulino V, McLaughlin L, Whelan A, Choo Ay, Weiner DB, Ugen KE. “Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice.”  Vaccine. 2006 May 22;24(21):4630-9. 
  39. Kwak and Haley WE.  “Current research findings on end-of-life decision making among racially/ethnically diverse groups.”  The Gerontologist, 2005;45:634-641
  40. Leighty, R.E., et al., “Use of multimeric statistical analysis to characterize and discriminate between the performance of four Alzheimer’s transgenic mouse lines differing in AB deposition,” Behavior Brain Res. 2004 Aug 12;153(1):107-121.
  41. Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci. 2006;26:11923-8
  42. Loewenstein DA, Acevdeo A, Agron J, Martinez G, Duara R.  “The use of amnestic and nonamnestic composite measures are different thresholds in the neuropsychological diagnosis of MCI.”  J Clin Exp Neuropsychol. 2007 Apr; 29(3):300-7
  43. Loewenstein DA, Acevedo A, Czaja SJ, Duara R.  “Cognitive rehabilitation of mildly impaired Alzheimer disease patients on cholinesterase inhibitors.”  Am J Geriatr Psychiatry. 2004 Jul-Aug; 12(4):395-402.
  44. Loewenstein, David A., et al., ”Cognitive Profiles in Alzheimer’s Disease and in Mild Cognitive Impairment of Different Etiologies,” Dement Geriatr Cogn Disord 2006;21:309-315.
  45. Loewenstein, David A., et al., ”Using Different Memory Cutoffs to Assess Mild Cognitive Impairment,” Am J Geriatr Psychiatry; 14:11, Nov 2006.
  46. Loewenstein DA, Acevedo A, Agron J, Duara R. Stability of neurocognitive impairment in different subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord. 2007;23:82-6.
  47. Luis CA, Barker WW, Loewenstein DA, Crum TA, Rogaeva E, Kawarai T, St George-Hyslop P, Duara R.  “Conversion to dementia among two groups with cognitive impairment. A preliminary report.”  Dement Geriatr Cogn Disord. 2004;18(3-4):307-13.
  48. Manoutcharian K, Acero G, Munguia ME, Becerril B, Massieu L, Govezensky T, Ortiz E, Marks JD, Cao C, Ugen K, Gevorkian G. “Human single chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid-beta 1-42.”  Neurobiol Dis. 2004 Oct;17(1):114-21.  
  49. Mittelman MS, Haley WE, Clay OJ, Roth DL. Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease. Neurology. 2006;67:1592-9
  50. Molinari V, Chiriboga DA, Schonfeld L, Haley WE, Schinka J, Hyer K and Dupree LW.  “Geropsychology post-doctoral training in public sector service delivery: The USF/Tampa VA Fellowship Model.” Gerontology and Geriatrics Education, 2005;25:63-82
  51. Mortimer JA, Borenstein AR, Gosche KM and Snowdon DA.  “Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression.”  J. Geriat. Psychiat. Neurol. 2005;18:218-223.
  52. Moykkynen T, Liebkind R, Sjoberg J, Korpi ER, Liesi P., “The neuroprotective KDI domain of gamma 1-laminin is a universal and potent inhibitor of ionotropic glutamate receptors,” J Neurosci Res. 2005 Sep 15;81(6):797-804.
  53. Nilsson, L. N.G., et al., “Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation,” Neurobiology of Aging 25: 1153-1167 (2004).
  54. Obregon D, Razai-Zadeh K, Bai Y, Sun N hou H, Ehrhart J, Zeng J, Mori T, Arendash GW, Shytle D, Town T, Tan J. “Adam10 Activition is Required for Green Tea-EGCg-Induced α-Secretase Clearvage of Amyloid Precursor Protein.”  The American Society for Biochemistry and Molecular Biology, Inc. 2006 Apr. 19.
  55. Obregon, Demian F., et al., ”ADAM10 Activation Is Required for Green Tea (-)-Epigallocatechin-3-gallate-induced alpha-Secretase Cleavage of Amyloid Precursor Protein,” J. Bio Chem; 281:24,16419-16427 Jun 26 2006.
  56. Ownby, R. L., et al., “Factors related to medication adherence in memory disorder clinic patients,” Ag & Mental Hlth; 10(4):378-385, Jul 2006.
  57. Padmanabhan J., Levy M., Dickson DW, Potter H.  “Alpha 1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer’s disease brain, induces tau phosphorylation in neurons.”  Brain 2006 Nov;129(Pt 11):3020-34.
  58. Ralston, L. “Handbook: Alzheimer’s: The Caregivers Handbook,” (2004).
  59. Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW, Coon KD, Liang WS, Herbert RH, Beach T, Rohrer KC, Zhao AS, Leung D, Bryden L, Marlowe L, Kaleem M, Mastroeni D, Grover A, Heward CB, Ravid R, Rogers, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Kukull W, Papassotiropoulos A, Stephan DA. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron. 2007 Jun 7;54(5):713-20.
  60. Rogaeva, Ekaterina, et al., “The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease,” Nature Genetics; [Epub 2007].
  61. Roth DL, Mittelman M., Clay O, Madan A and Haley WE.  “Changes in social support as mediators of the impact of psychosocial intervention for spouse caregivers of persons with Alzheimer’s disease.”   Psychology and Aging, 2005;20:634-644.
  62. Salvatierra J., Rosselli M., Acevedo A., Duara R.  “Verbal fluency in bilingual Spanish/English Alzheimer’s disease patients.”  Am J Alzheimers Dis Other Demen. 2007 Jun-Jul; 22(3):190-201.
  63. Schinka JA, McBride A, Vanderploeg RD, Tennyson K, Borenstein AR and Mortimer JA.  “Florida cognitive activities scale:  Initial development and validation.”  J. Int. Neuropsychol. Soc. 2005;11:108-116.
  64. Shibata N, Kawarai T, Lee JH, Lee HS, Shibata E, Sato C, Liang Y, Duara R, Mayeux RP, St George-Hyslop PH, Rogaeva E.  “Association studies of cholesterol metabolism genes (CH25H, ABCA1 and CH24H) in Alzheimer's disease.”  Neurosci Lett. 2006;391(3):142-6.
  65. Shibata, Nobuto, et al., “Association studies between the plasmin genes and late-onset Alzheimer’s disease,” J.Neurobiolaging; 2006.05.028.
  66. Shytle, R.D., et al., “Cholinergic Modulation of Microglial Activation by α7 Nicotinic Receptors,” Journal of Neurochemistry, 89:337-343 (2004).
  67. Suo, Zhiming, et al., “GRK5 deficiency leads to early Alzheimer-like pathology and working memory impairment,” Neurobiol of Aging; 2006 Aug 29 [Article in press].
  68. Tan, J., et al., “Green Tea Eipgallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice,” J. Neurosci., 25(38):8807-14, (2005).
  69. Tolentino, P.J., et al., “Increased Expression of Tissue-Type Transglutaminase Following Middle Cerebral Artery Occlusion in Rats,” Journal of Neurochemistry, 89:1301-7(2004).
  70. Townsend, K.P., et al., “Lovastatin Modulation of Microglial Activation Via Suppression of Functional CD40 Expression,” Journal of Neuroscience Research, 78:167-176 (2004).
  71. Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol. 2006;65:685-97.
  72. Vaananen AJ, Rauhala P, Tuominen RK, Liesi P., “KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity, “ J Neurosci Res. 2006 Aug 15;84(3):655-65.
  73. Wahi, M., et al.,  “A Study of Results Generated Using the Abbott LCx-GC Assay Fails to Reveal a Performance-Based Rationale for the 2002 Level I Recall,” Am. J. Clin. Pathol., 123(6):809-16 (2005).
  74. Wiksten, M. et al., “Regeneration of Adult Rat Spinal Cord is Promoted by the Soluble KDI Domain of γ1 Laminin,” J. Neurosc. Res., 78(d):403-10 (2004).
  75. Wiksten, M., et al., “Soluble KDI Domain of Y1 Laminin Protects Adult Hippocampus From Excitotoxicity of Kainic Acid,” J. Neurosc. Res., 78(3):411-19 (2004).
  76. Wilcock DM, Gordon MN, Morgan D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc. 2006;1:1591-5.
  77. Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience. 2007;144:950-60.
  78. Woodruff, B.K., et al., “Family history of dementia is a risk factor for Lewy body disease,” Am.Acad.Neurol 2006;66;1949-1950.